Pharmaceutical companies have spent years targeting a common blood particle associated with heart-attack risks.

Drugmaker Eli Lilly is testing a new experimental drug that could be a game changer in treating high cholesterol, it said.

An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...

One and done? Pharma giant Eli Lilly announced Monday that its gene-editing therapy can reduce LDL (“bad”) cholesterol by up to 62% with a single infusion. Not only was the experimental treatment ...

A one-time gene-editing infusion kept cholesterol levels low for a year, offering a potential new approach to preventing ...

Patients in London have received a pioneering new gene editing therapy that lowers "bad" cholesterol after a single infusion, ...

A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point ...

A groundbreaking gene-editing therapy developed by Eli Lilly and Verve Therapeutics reduced "bad" LDL cholesterol by up to 62 ...

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

The future of cholesterol-lowering drugs is nearing; CVS sues Tennessee over PBM law; Trump administration moves to ...